Universiteit Leiden
- Address
- lock Available on a paid plan
Immune System Diseases and Nephrology Research
At Universiteit Leiden, the Division of Nephrology is involved in clinical studies focused on immune system diseases and immune system processes, with a strong emphasis on kidney transplant rejection. This research is centered on testing new approaches that may help improve transplant outcomes and support safer long-term care for transplant recipients.
- Study of kidney transplant rejection and prophylaxis against renal transplant rejection
- Evaluation of a new cell-based therapy aimed at improving transplant tolerance
- Assessment of treatment safety and durability in renal transplant care
The trials here reflect a broader effort to advance transplant medicine by exploring therapies that may reduce rejection risk and improve the long-term success of kidney transplantation.
Hepatic Disease and Gastroenterology Studies
Clinical research at this site also includes work on alcoholic liver cirrhosis and related complications, especially in patients undergoing Transjugular Intrahepatic Portosystemic Shunt placement. These studies are designed to improve prevention and supportive care for serious liver-related complications.
- Investigation of hepatic encephalopathy prevention in liver cirrhosis
- Comparison of standard preventive treatment approaches with placebo
- Focus on reducing complications after TIPS procedures
This area of research aims to refine treatment strategies for advanced liver disease and improve the safety of procedures used in patients with complex cirrhosis.
Transplant Immunology and Long-Term Safety Research
The clinical trial portfolio at Universiteit Leiden includes studies that follow patients over time to understand the lasting effects of emerging therapies in renal transplantation. The main goal is to evaluate whether novel interventions remain safe and well tolerated while supporting immune control after treatment.
- Long-term monitoring of autologous cell therapy in living donor kidney transplant recipients
- Investigation of sustained safety and tolerability after treatment
- Research into improved approaches for preventing transplant rejection
These studies contribute to the development of more durable immunology-based strategies for patients who need lifelong transplant care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Amsterdam UMC Stichting1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universiteit Leiden
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study Comparing Sigvotatug Vedotin and Docetaxel in Adults with Previously Treated Non-Small Cell Lung Cancer | Seagen Inc. | Phase III | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Tx200-Tr101 | 2 | Unknown | 2021-03-17 | 2023-07-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.